These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 24196332)

  • 1. Identifying patients at risk for recurrent or advanced BCC.
    Hamid O; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current landscape for treatment of advanced basal cell carcinoma.
    Foley P
    Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining locally advanced Basal cell carcinoma.
    Maly TJ; Sligh JE
    J Drugs Dermatol; 2014 May; 13(5):528-9. PubMed ID: 24809873
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease.
    Goldenberg G; Hamid O
    J Drugs Dermatol; 2013 Dec; 12(12):1369-78. PubMed ID: 24301238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of high-risk and advanced basal cell carcinoma.
    Puig S; Berrocal A
    Clin Transl Oncol; 2015 Jul; 17(7):497-503. PubMed ID: 25643667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.